|
|
Proposal of Investment Portfolio of Qualified Investors Fund
Václavík, Lukáš ; Ptáček, Roman (referee) ; Rejnuš, Oldřich (advisor)
The diploma thesis deals with the financial analysis of European joint stock companies in the pharmaceutical sector in order to expand the investment portfolio of a field-oriented fund of qualified investors. Selected companies are subjected to financial analysis by selected ratios. Based on these data, they are compared with each other by the method of intercompany comparison according to specified weights and verified in terms of their possible bankruptcy. With the help of these outputs, a proposal to expand the fund's investment portfolio is subsequently formulated.
|
|
|
Proposal of Investment Portfolio of Qualified Investors Fund
Václavík, Lukáš ; Ptáček, Roman (referee) ; Rejnuš, Oldřich (advisor)
The diploma thesis deals with the financial analysis of European joint stock companies in the pharmaceutical sector in order to expand the investment portfolio of a field-oriented fund of qualified investors. Selected companies are subjected to financial analysis by selected ratios. Based on these data, they are compared with each other by the method of intercompany comparison according to specified weights and verified in terms of their possible bankruptcy. With the help of these outputs, a proposal to expand the fund's investment portfolio is subsequently formulated.
|
|
|
EU Competition Law and Practices Hindering Market Entry of Drugs
Křešová, Karolína ; Šmejkal, Václav (advisor) ; Svobodová, Magdaléna (referee)
EU Competition Law and Practices Hindering Market Entry of Drugs This thesis deals with the legality of pharmaceutical companies' practices that hinder market entry of drugs, whether within the intra-brand or inter-brand competition, from the EU competition law perspective. The aim of this thesis is to introduce the reader to the issue of different practices aimed at limiting parallel trade and also at delaying or complete prevention of the market entry of a new competing drug, and also to assess whether the competition authorities have established clear guidance on the performance of these practices, i.e. whether they are clearly set boundaries between acceptable restriction of competition which can be justified and distortion which cannot be allowed. For the purpose of this assessment, the relevant decisions of the European Commission and the CJEU are analyzed, identifying the key factors on which the competition authorities place emphasis when assessing the compliance of such practices with the EU competition law, and general conclusions are drawn from these key factors to determine whether there is a sufficient degree of legal certainty for pharmaceutical companies engaging in these practices. The thesis is divided into six chapters, of which chapters three, four and five form the main part....
|
|
|
Lobbying in the USA – The analysis of lobbying spending
Hazalová, Jana ; Vymětal, Petr (advisor) ; Müller, Karel (referee)
Lobbying spending is a current and often discussed topic in the United States. Despite plenty of publications about lobbying only few of them deal with lobbying spending. Those are the essential reasons for choosing this topic. This work focuses on complex analyses of lobbying spending and attempts to answer three questions: who are the top spenders, how much do they spend on lobbying and on which purpose between the period 2001 and 2011. The text is divided into three chapters. The first chapter deals with lobbying definition, its history in the USA and the current legislation. The second chapter analyses top industries and top lobbying spenders. The third chapter discusses the spending of pharmaceutical industry. Both last chapters have the same structure. At first, the particular subjects and overall spending are presented. The next part analyses development of spending and the aim of their use.
|
|
|
Investment analysis of Biotechnology and Pharmaceuticals sector
Pavúk, Šimon ; Musílek, Petr (advisor) ; Polák, Michal (referee)
The principal aim of this thesis is to describe methods of fundamental analysis of three major companies from sectors of Biotechnology and Pharmaceuticals, namely Johnson & Johnson, Pfizer and Amgen. Among used methods we are able to find 2 -- stage discounted cashlow models Free-cashflow-to-equity FCFE and Free-cashflow-to-firm FCFF, Gordon's dividend discount model a relative valuation methods using P/E, P/BV and P/S. Descriptive part of this thesis describes legal and regulatory environment, which has significant impact on the development process of new innovative drugs and therapies. Further it sets investment recommendations and looks closer at investment opportunities in biotechnological companies.
|
guest ::
